Will BPC-157 become legal? The PCAC review

By The Docket DeskResearched & sourcedUpdated 18 Jun 2026

The short answer

The FDA’s Pharmacy Compounding Advisory Committee reviews BPC-157 on July 23, 2026. It is currently not FDA-approved and not legal to compound; the vote is the first formal step toward potential legal compounding.

FDA approvalNot approved

Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized

Under FDA reviewPCAC · July 23, 2026

Use under reviewUlcerative colitis

Earliest pharmacy accessLate 2026–Q1 2027 (if cleared)

A committee “yes” is a recommendation, not legalization. The path has two stages: first the PCAC vote, then formal FDA rulemaking. Each peptide effectively turns on both — which is why a favorable vote still doesn’t mean you can fill a prescription the next day.

What happens on July 23

The FDA’s Pharmacy Compounding Advisory Committee will hear evidence and vote on whether BPC-157 should be added to the 503A list for ulcerative colitis. A “yes” is a recommendation only; the FDA would then need to issue a final rule before any pharmacy could legally compound it. Realistic patient access, if it happens at all, is late 2026 to early 2027.

Will BPC-157 become legal in 2026?+

Not automatically. The committee meets July 23, 2026; a favorable vote is a recommendation only — the FDA must then issue a final rule, which typically takes months. Realistic legal compounded access is late 2026 to Q1 2027, and only if both steps go through.

Is “research-grade” BPC-157 the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.